iPSC-Derived Cardiomyocytes as a Disease Model to Understand the Biology of Congenital Heart Defects.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Myocytes, Cardiac*/metabolism ; Myocytes, Cardiac*/pathology ; Induced Pluripotent Stem Cells*/metabolism ; Induced Pluripotent Stem Cells*/cytology ; Heart Defects, Congenital*/pathology ; Heart Defects, Congenital*/genetics ; Cell Differentiation*; Humans ; Animals ; Models, Biological

The discovery of human pluripotent stem cells (hiPSCs) and advances in DNA editing techniques have opened opportunities for personalized cell-based therapies for a wide spectrum of diseases. It has gained importance as a valuable tool to investigate genetic and functional variations in congenital heart defects (CHDs), enabling the customization of treatment strategies. The ability to understand the disease process specific to the individual patient of interest provides this technology with a significant advantage over generic animal models. However, its utility as a disease-in-a-dish model requires identifying effective and efficient differentiation protocols that accurately reproduce disease traits. Currently, iPSC-related research relies heavily on the quality of cells and the properties of the differentiation technique In this review, we discuss the utility of iPSCs in bench CHD research, the molecular pathways involved in the differentiation of cardiomyocytes, and their applications in CHD disease modeling, therapeutics, and drug application.

Cell Rep. 2019 Jan 15;26(3):720-732.e4. (PMID: 30650362)
N Engl J Med. 2010 Oct 7;363(15):1397-409. (PMID: 20660394)
Science. 2008 Aug 29;321(5893):1218-21. (PMID: 18669821)
Development. 2006 Apr;133(8):1575-85. (PMID: 16556916)
Stem Cell Reports. 2019 Oct 8;13(4):657-668. (PMID: 31564645)
Circulation. 2000 Sep 5;102(10):1178-85. (PMID: 10973849)
Dev Dyn. 2008 Jun;237(6):1627-35. (PMID: 18498088)
Circ Res. 2019 Feb 15;124(4):553-563. (PMID: 30582441)
Cell. 2008 Apr 18;133(2):250-64. (PMID: 18423197)
PLoS One. 2014 Jul 22;9(7):e102796. (PMID: 25050861)
Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):29-33. (PMID: 24932360)
Circ Res. 2020 Mar 27;126(7):923-925. (PMID: 32070195)
Cell Stem Cell. 2007 Aug 16;1(2):165-79. (PMID: 18371348)
Nat Rev Genet. 2011 Apr;12(4):231-42. (PMID: 21339765)
Acta Biochim Biophys Sin (Shanghai). 2018 Oct 1;50(10):941-949. (PMID: 30165534)
Stem Cell Res Ther. 2022 Dec 27;13(1):531. (PMID: 36575473)
Genes Dev. 1995 Dec 15;9(24):3027-37. (PMID: 8543149)
Mol Biol Cell. 2017 Jul 7;28(14):1871-1882. (PMID: 28468977)
Nat Rev Cardiol. 2020 Jun;17(6):341-359. (PMID: 32015528)
Medicine (Baltimore). 2022 Aug 19;101(33):e30123. (PMID: 35984151)
Front Cell Dev Biol. 2015 Feb 02;3:2. (PMID: 25699255)
Genes Dev. 2005 Feb 1;19(3):387-96. (PMID: 15687261)
Cell Stem Cell. 2008 Nov 6;3(5):568-74. (PMID: 18983970)
Nat Rev Cardiol. 2018 Nov;15(11):685-704. (PMID: 30287945)
Cells. 2024 Jan 11;13(2):. (PMID: 38247824)
J Am Heart Assoc. 2020 Oct 20;9(20):e016528. (PMID: 33059525)
Cardiovasc Res. 2012 Sep 1;95(4):419-29. (PMID: 22739119)
Biomed Pharmacother. 2023 Jan;157:113970. (PMID: 36371854)
Sci Rep. 2020 Jul 2;10(1):10921. (PMID: 32616843)
Genes Dev. 2022 Jun 1;36(11-12):652-663. (PMID: 35835508)
Front Cell Dev Biol. 2020 Jun 23;8:440. (PMID: 32656206)
Circulation. 2024 Mar 12;149(11):888-891. (PMID: 38466780)
Front Cardiovasc Med. 2023 Sep 28;10:1249605. (PMID: 37840956)
Genes Dev. 1995 Sep 1;9(17):2105-16. (PMID: 7657163)
Hum Mutat. 2012 Jan;33(1):86-90. (PMID: 21922595)
Nat Biotechnol. 2008 Nov;26(11):1269-75. (PMID: 18849973)
Circ Res. 2014 Jan 17;114(2):354-67. (PMID: 24436431)
Int J Mol Sci. 2020 Jun 19;21(12):. (PMID: 32575374)
Nat Rev Drug Discov. 2017 Feb;16(2):115-130. (PMID: 27980341)
Heart. 2022 Mar;108(5):332-338. (PMID: 34039680)
Cardiovasc Res. 2018 Dec 1;114(14):1828-1842. (PMID: 30169602)
Cardiovasc Drugs Ther. 2017 Jun;31(3):325-344. (PMID: 28721524)
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18531-6. (PMID: 18000065)
Bioengineering (Basel). 2023 Feb 10;10(2):. (PMID: 36829731)
Cell Res. 2011 Sep;21(9):1305-15. (PMID: 21709693)
Toxicol Sci. 2016 Jul;152(1):99-112. (PMID: 27125969)
Cell Stem Cell. 2022 May 5;29(5):840-855.e7. (PMID: 35395180)
ChemMedChem. 2021 Nov 5;16(21):3300-3305. (PMID: 34309224)
Circ Res. 2015 Jun 19;117(1):80-8. (PMID: 26089365)
Hum Mol Genet. 2014 Jan 1;23(1):78-89. (PMID: 23945394)
Circulation. 2020 Oct 20;142(16):1605-1608. (PMID: 33074758)
Hum Mol Genet. 2017 Aug 15;26(16):3031-3045. (PMID: 28521042)
Sci Rep. 2020 Oct 28;10(1):18498. (PMID: 33116175)
Cell Stem Cell. 2020 Oct 1;27(4):574-589.e8. (PMID: 32810435)
Stem Cells. 2008 Aug;26(8):1998-2005. (PMID: 18511599)
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9319-24. (PMID: 17519332)
Curr Probl Cardiol. 1997 Jun;22(6):297-351. (PMID: 9189673)
Stem Cells Transl Med. 2014 Apr;3(4):416-23. (PMID: 24591732)
Genet Med. 2006 Mar;8(3):143-55. (PMID: 16540748)
Semin Cell Dev Biol. 2020 Apr;100:29-51. (PMID: 31862220)
Circulation. 2008 Apr 29;117(17):2178-80. (PMID: 18443247)
Cells. 2022 Aug 11;11(16):. (PMID: 36010573)
Expert Rev Mol Med. 2023 Jan 04;25:e5. (PMID: 36597672)
Dev Dyn. 2008 Apr;237(4):1144-52. (PMID: 18330927)
J Genet. 2021;100:. (PMID: 33707356)
Science. 2007 Dec 21;318(5858):1917-20. (PMID: 18029452)
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13742-7. (PMID: 20643952)
Sci Rep. 2022 Oct 18;12(1):17409. (PMID: 36257968)
Sci Rep. 2023 Mar 9;13(1):3920. (PMID: 36894665)
Stem Cells Transl Med. 2021 Feb;10(2):198-208. (PMID: 32946199)

Keywords: TOF; cardiomyocyte; congenital heart diseases; disease model; iPSC

Date Created: 20240914 Date Completed: 20240914 Latest Revision: 20250124

20250125

PMC11393881

10.3390/cells13171430

39273002